Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q64921321 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241221010730.0 | ||
| 008 | 241221nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q64921321 | ||
| 024 | ‡a 0000-0003-4571-654X ‡2 orcid | ||
| 035 | ‡a (OCoLC)Q64921321 | ||
| 100 | 0 | ‡a Giacomo M Bruno ‡c researcher ‡9 en | |
| 375 | ‡a 1 ‡2 iso5218 | ||
| 400 | 0 | ‡a Giacomo M Bruno ‡c wetenschapper ‡9 nl | |
| 400 | 0 | ‡a Giacomo M Bruno ‡c investigador ‡9 es | |
| 670 | ‡a Author's Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. | ||
| 670 | ‡a Author's Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes. | ||
| 670 | ‡a Author's Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study | ||
| 670 | ‡a Author's Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study | ||
| 670 | ‡a Author's The preventive effect on respiratory tract infections of Oscillococcinum®. A cost-effectiveness analysis. | ||
| 909 | ‡a (orcid) 000000034571654x ‡9 1 | ||
| 919 | ‡a budgetimpactmodelofsecukinumabforthetreatmentofmoderatetoseverepsoriasispsoriaticarthritisandankylosingspondylitisinitalyacrossindicationinitiative ‡A Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. ‡9 1 | ||
| 919 | ‡a costminimizationanalysisofdegludecliraglutideversusglargineasparteconomicimplicationsofthedual7studyoutcomes ‡A Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes. ‡9 1 | ||
| 919 | ‡a economicevaluationofdulaglutidevstraditionaltherapiesimplicationsoftheoutcomesoftherewindstudy ‡A Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study ‡9 1 | ||
| 919 | ‡a omalizumabforsevereallergicasthmatreatmentinitalyacosteffectivenessanalysisfromproximastudy ‡A Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study ‡9 1 | ||
| 919 | ‡a preventiveeffectonrespiratorytractinfectionsofoscillococcinumacosteffectivenessanalysis ‡A The preventive effect on respiratory tract infections of Oscillococcinum®. A cost-effectiveness analysis. ‡9 1 | ||
| 946 | ‡a b ‡9 1 | ||
| 996 | ‡2 ICCU|UFIV073730 | ||
| 996 | ‡2 BNF|16229320 | ||
| 996 | ‡2 CAOONL|ncf11427709 | ||
| 996 | ‡2 NKC|xx0054350 | ||
| 996 | ‡2 ISNI|0000000061599708 | ||
| 996 | ‡2 DNB|1081698551 | ||
| 996 | ‡2 PLWABN|9810673945305606 | ||
| 996 | ‡2 LC|n 83007700 | ||
| 996 | ‡2 PTBNP|1416566 | ||
| 996 | ‡2 PTBNP|178344 | ||
| 996 | ‡2 DNB|116812222 | ||
| 996 | ‡2 W2Z|1533887356502 | ||
| 996 | ‡2 SUDOC|030425581 | ||
| 996 | ‡2 NLA|000052033032 | ||
| 996 | ‡2 NSK|000708376 | ||
| 996 | ‡2 PLWABN|9812477158905606 | ||
| 996 | ‡2 DNB|119631326 | ||
| 996 | ‡2 LC|n 84115867 | ||
| 996 | ‡2 ISNI|0000000111883214 | ||
| 996 | ‡2 BNE|XX1378680 | ||
| 996 | ‡2 BNE|XX1408926 | ||
| 996 | ‡2 SUDOC|223656747 | ||
| 996 | ‡2 SUDOC|277222117 | ||
| 996 | ‡2 DNB|1340775913 | ||
| 996 | ‡2 LNB|LNC10-000261182 | ||
| 996 | ‡2 RERO|A018890215 | ||
| 996 | ‡2 SUDOC|17666100X | ||
| 996 | ‡2 BNE|XX4734092 | ||
| 996 | ‡2 PLWABN|9810601732505606 | ||
| 996 | ‡2 RERO|A005540058 | ||
| 996 | ‡2 PLWABN|9813168447005606 | ||
| 996 | ‡2 DNB|106300019X | ||
| 996 | ‡2 SUDOC|08603328X | ||
| 996 | ‡2 LIH|LNB:B_l_TP;=B_o_ | ||
| 996 | ‡2 BNF|14850203 | ||
| 996 | ‡2 J9U|987007278498905171 | ||
| 996 | ‡2 BNF|11894378 | ||
| 996 | ‡2 DNB|1038102502 | ||
| 996 | ‡2 BAV|495_10459 | ||
| 996 | ‡2 BNC|981058508235306706 | ||
| 996 | ‡2 BNF|12184179 | ||
| 996 | ‡2 CAOONL|ncf10706493 | ||
| 996 | ‡2 NTA|073651354 | ||
| 996 | ‡2 NLR|RU NLR AUTH 77111397 | ||
| 996 | ‡2 BAV|495_91539 | ||
| 996 | ‡2 SUDOC|27956712X | ||
| 996 | ‡2 DNB|1053405421 | ||
| 996 | ‡2 BNC|981058594952306706 | ||
| 996 | ‡2 PLWABN|9813318704005606 | ||
| 996 | ‡2 DNB|115361324 | ||
| 996 | ‡2 NUKAT|n 2012161103 | ||
| 996 | ‡2 ISNI|0000000069103703 | ||
| 996 | ‡2 NUKAT|n 2006123456 | ||
| 996 | ‡2 ISNI|0000000002954335 | ||
| 996 | ‡2 BIBSYS|90245450 | ||
| 996 | ‡2 LC|n 2021007146 | ||
| 996 | ‡2 BNF|12546693 | ||
| 996 | ‡2 ICCU|CUBV140485 | ||
| 996 | ‡2 LIH|LNB:C_b__h__h_;=B, | ||
| 996 | ‡2 SELIBR|324864 | ||
| 996 | ‡2 NUKAT|n 97071387 | ||
| 996 | ‡2 BNE|XX6523338 | ||
| 996 | ‡2 BNF|14530085 | ||
| 996 | ‡2 SUDOC|280829876 | ||
| 996 | ‡2 ISNI|0000000030117323 | ||
| 996 | ‡2 NTA|074108689 | ||
| 996 | ‡2 NTA|070593965 | ||
| 996 | ‡2 BLBNB|000471857 | ||
| 996 | ‡2 ISNI|0000000071004528 | ||
| 996 | ‡2 J9U|987007576697405171 | ||
| 996 | ‡2 NTA|074494945 | ||
| 996 | ‡2 ICCU|TO0V269659 | ||
| 996 | ‡2 NTA|297203428 | ||
| 996 | ‡2 LC|n 88117382 | ||
| 996 | ‡2 PTBNP|182057 | ||
| 996 | ‡2 J9U|987007273815705171 | ||
| 996 | ‡2 J9U|987007271154305171 | ||
| 996 | ‡2 NTA|245603093 | ||
| 996 | ‡2 NDL|00832677 | ||
| 996 | ‡2 BIBSYS|90815484 | ||
| 996 | ‡2 LC|n 2005032106 | ||
| 996 | ‡2 BAV|495_349650 | ||
| 996 | ‡2 CAOONL|ncf10680296 | ||
| 996 | ‡2 BIBSYS|1533887356502 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
